High hopes for cannabinoid agonists in the treatment of rheumatic diseases by Staunton, Caroline A et al.
Staunton et al. BMC Musculoskeletal Disorders 2014, 15:410
http://www.biomedcentral.com/1471-2474/15/410COMMENTARY Open AccessHigh hopes for cannabinoid agonists in the
treatment of rheumatic diseases
Caroline A Staunton1, Ali Mobasheri2,3,4,5 and Richard Barrett-Jolley1,2*Abstract
There are two well-characterised isoforms of cannabinoid receptor; CB1 and CB2 and of these CB2 is under active
investigation as a potential target for treatment of the chronic pain associated with widespread and intractable
joint diseases osteoarthritis and rheumatoid arthritis. The recent report by Fukuda et al (BMC Musculoskelet Disord
15:275, 2014) in BMC Musculoskeletal Disorders investigates the efficacy of a selective CB2 agonist, JW133, in both
in vitro and in vivo models of rheumatoid arthritis and provides encouraging data. The report shows that JW133
inhibits expression of the CCL2 cytokine, osteoclastogenesis and reduces histological indicators of joint degeneration.
Each of these could potentially contribute to beneficial analgesic effects in a therapeutic context.
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The cannabinoids are a family of compounds from the
plant Cannabis sativa L. (sativa meaning useful) the
well-known being the alkaloid Δ9 tetrahydrocannabinol
(THC). Recent years have seen an explosion of complexity
in the field of cannabinoid pharmacology. It was discov-
ered quite early that there were potentially a number of
active constituents of the plant and there were two clearly
distinguishable receptor subtypes CB1 and CB2 [1,2], but
more recently this list is looking likely to grow, as former
so called orphan G-protein coupled receptors such as
GPR55 [3] and potentially GPR18 [4] emerge as recep-
tors for cannabinoids. Furthermore there are well-known
ion channels, such as TRPV1 and other proteins such
as nuclear peroxisome proliferator-activated receptors
(PPAR’s) that appear to be modulated by cannabinoids
[5]. This already multifaceted story has started to now
become even more complex with the identification of
not just agonists, but antagonists, allosteric modulators
[6] and inverse agonists [7]. The most basic summary of
cannabinoid pharmacology indicates that CB1 is generally* Correspondence: RBJ@liv.ac.uk
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unless otherwise stated.located to neurones and the CNS [8] and CB2 located else-
where [1]. Naturally every rule has its exceptions. For ex-
ample many assume that CB2 receptors are not expressed
in brain, this is in fact inaccurate; although expression of
this receptor can be induced in immune cells, they are
resident in brain microglia or simply infiltrating immune
cells [9]. Cannabinoid receptors are therefore present in
the inflammatory pain pathway at both the peripheral and
central (spinal and supraspinal) levels [10]. The expression
of CB1 is largely restricted to neuronal cells and in par-
ticular those neuronal cells responsible for nociceptive
processing within the brain and the peripheral nervous
system [8]. CB2 receptor expression is predominantly
restricted to immune cells including glia and in the con-
text of this editorial it was originally identified in macro-
phages [1,11] (See Figure 1). It is probably too early to be
too categorical about the other emerging subtypes.
Enthusiasm for cannabinoids as medicines seems to go
through phases. Firstly, it was thought of as a recreational
drug; then potential medicinal benefits emerged and later
as the widespread (approaching pleiotropic) actions were
identified it started to appear as if their actions were too
widespread to biomedical and pharmaceutical utility. The
discovery of a positive interaction between cannabinoid
ligands and TRPV1 was particularly disappointing, since
TRPV1 is a widespread mediator of joint nociception [14].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Cannabinoids have multiple actions in the synovium. The synovium is a richly vascularised and innervated tissue that becomes
inflamed in both RA [12] and OA [13]. Fibroblast-like synovial cells (FLS) lie at the heart of synovial tissue; producing synovial fluid and mediating
both pro- and anti-inflammatory properties of the synovium. A number of cytokines act on the FLS and induce release of further cytokines. The
CB2 receptor is expressed more in the RA synovium than that of the OA joint. Production of CCL2, MMP-3 and IL-6 were all suppressed by the
selective CB2 agonist JWH133 applied to in TNF-α stimulated FLS. Monocyte osteoclastogenesis was also suppressed. These factors are all important in
arthritis. IL-6 mediates pain, MMP-3 mediates cartilage destruction and CCL-2 is a monocyte chemoattractant protein. Monocytes giving rise to osteoclasts
(which re-absorb bone) and infiltrating macrophages that perpetuate inflammation. Action of cannabinoids will prove more complex however
in complete joints, since CB2 receptors interact with TRPV1 and have been reported to increase afferent nerve firing [14], and chondrocytes express both
CB1 and CB2 under some conditions [15].
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returning to the field of medicinal cannabinoid research.
Main text
The separation of CB1 and CB2 implies that activation of
CB2 will be without psychotropic effects and so consider-
able efforts have gone into selective ligands for this recep-
tor in particular. A series of analogues were produced by
Huffman et al [16] and the paper published by Fukuda
et al 2014 in BMC Musculoskeletal Disorders [17] explores
one of these JWH133 in the context of rheumatology.
Joint pharmacology is an often-overlooked area of
research, despite the clear need for novel treatments for a
range of disorders. The overall burden of musculoskeletaldisease to society is enormous with the majority of elderly
people affected. A large part of this is arthritis; the two
most common subtypes of which are rheumatoid arthritis
(RA), an autoimmune disease that typically progresses
to all joints and osteoarthritis (OA), a condition with
multiple and less well-defined aetiologies. Although the
global prevalence of RA itself is modest (0.24%), the disease
is severe and protracted and is therefore a major contribu-
tor to pain and disability accounting for approximately
5 million disability-adjusted life years (DALYs) in 2010
[18]. In 2002 WHO ranked OA and RA as the first and
second largest individual causes of “years lived with dis-
ability” (YLD) [19] and the more recent and comprehensive
2010 Global Burden of Disease study placed musculoskeletal
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world apart from mental health conditions [20].
Synovitis is increasingly viewed as a pathogenic fac-
tor in arthritic diseases. In OA, synovitis is common
[13,21,22], but in RA it is the central component [23,24].
A number of potential treatments are available to reduce
pain generally (NSAIDs or paracetamol), or inflammation
in RA and OA however control of rheumatic pain specific-
ally is difficult. Latest treatments for RA include biological
interventions that interfere with TNF-α signalling and the
recent discovery of interactions between cartilage and sub-
chondral bone [25] mediated by NGF and the FGF family
of peptides has brought some excitement to treatment of
OA in particular [26]. Both sprifermin (human recombin-
ant FGF-18) and tanezumab (anti-NFG monoclonal anti-
body) [27] are both showing promise. Non-peptide drugs
are also frequently advantageous over peptides due to their
(often) greater ease of preparation and usage. The syno-
vium contains sensory nerve endings however and a clear
source of pain; probably in both RA and OA. Whilst a
considerable amount is known about the pharmacology
of chondrocytes [28], considerably less is known about
equally important synovial cells. In fact the synovium
as a whole has received less attention that the other
joint tissues, partly due to its relative inaccessibility and
fragility in a typical rodent model. Interestingly, however,
the major cellular component of the normal synovium is
type B or fibroblast-like synoviocyte (FLS) and these can
be isolated from humans [29] and larger animals [30], but
even relatively straightforwardly, from rodents [31]. A
well-established contributor of joint inflammation is the
infiltration of synovial macrophages. Macrophages express
CB2 receptors, and additionally, cannabinoid receptors are
expressed on neuronal cells. Therefore there is scope for a
complex pattern of cannabinoid interactions within the
synovium and surrounding joint tissue. Fukoda et al [17]
now test the efficacy of the 200 fold selective CB2 agonist
JWH133 against both FLS inflammation and the murine
collagen type II (CII)-induced arthritis (CIA) model of RA.
They find widespread and encouraging results. In vitro,
they culture FLS from RA patients and show that FLS pro-
duce IL-6, MMP-3, and CCL2 (also known as monocyte
chemotactic protein, MCP-1) in response to TNF-α stimu-
lation. This is interesting at a number of levels; IL-6 is
known to induce pain [32,33]. MMP-3 has roles in matrix
turn over and may diffuse from the synovium into car-
tilage in parallel to MMP-13 [34]. CCL2 is known to be
elevated in RA samples [35], this is a chemokine often
referred to as MCP1 and is involved in the recruitment
of monocytes, macrophages, T-cells and dendritic cells
to the sites of inflammation. Fukoda et al [17] also
showed how the promising JWH133 was able to inhibit
CCL2 expression. There were other observations too. For
example, JWH133 inhibited markers of osteoclastogenesisand this too could have implications for preservation of
bone loss in RA. Osteoclastogenesis is a multi-complex
procedure that includes many stages, and each one of
which is a potential therapeutic target in OA [36] and
many other diseases including osteoporosis [37]. This is
an additional promising role for JWH133 and fits nicely
with the observation CB2-deficient mice develop osteo-
porosis with age [37] and that JWH133 attenuated pain
behaviours in a rat model of OA [38]. Fukuda et al ob-
served [17] an over-all reduction in arthritic “score” in
CIA mice injected with JWH133 compared to controls,
again enforcing the potential for JWH133.Conclusions
Musculoskeletal biology has been in need of a selective
CB2 agonist in arthritic models. The apparent beneficial
effects reported here are comparatively mild, but could
be synergistic to each other with benefits in terms of
reduced pain, reduced inflammatory activity and reduced
osteoclastogenesis of infiltrating macrophages. This is
the first report of positive effects of a selective CB2
agonist in the CIA model. Although the effect was mild,
optimization of dosage and/or treatment protocol might
enhance the effect. Perhaps, even more selective CB2 ago-
nists might solve this problem. JWH133 is approximately
200 fold selective (CB2/CB1) [16] and the future may see
selectivity orders of magnitude greater than this in the
near future. So this study is early; but very encouraging,
providing yet more evidence [39] that the therapeutic
potential of cannabis extracts, and its analogues are
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